Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
复制标题

双特异性 T 细胞接合器:一种治疗血液恶性肿瘤的新兴疗法。

DOI:
10.1186/s13045-021-01084-4
复制
发表时间:
2021-05-03
影响因子:
28.5
通讯作者:
Wang X
Wang X
中科院分区:
医学1区
文献类型:
--
作者:
Tian Z;Liu M;Zhang Y;Wang X

文献摘要

参考文献

被引文献

相似文献

利用免疫细胞,特别是T细胞的力量来增强抗肿瘤活性已成为血液恶性肿瘤临床管理中有前途的策略。新兴的双特异性抗体(BsAbs),其将T细胞募集至肿瘤细胞,以双特异性T细胞粘附分子(BiTEs)为例,促进了肿瘤免疫治疗的发展。在这里,我们讨论了BiTE治疗血液系统恶性肿瘤的进展和挑战。Blinatumomab是首个获批用于治疗急性淋巴细胞白血病(ALL)的BiTE,因其高效性和安全性而备受赞赏。最近的研究集中在通过优化治疗方案和改进BiTEs的分子结构来提高BiTEs的疗效。大量在血液恶性肿瘤中潜在有效的双特异性T细胞募集抗体已衍生自BiTE。BiTE作用机制的阐明和用于构建BsAb的新生技术可以改善血液恶性肿瘤的治疗。本文综述了双特异性T细胞募集抗体治疗血液系统恶性肿瘤的特点,重点介绍了其临床前实验和临床研究。
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (BiTEs), have facilitated the development of tumor immunotherapy. Here we discussed the advances and challenges in BiTE therapy developed for the treatment of hematologic malignancies. Blinatumomab, the first BiTE approved for the treatment of acute lymphocytic leukemia (ALL), is appreciated for its high efficacy and safety. Recent studies have focused on improving the efficacy of BiTEs by optimizing treatment regimens and refining the molecular structures of BiTEs. A considerable number of bispecific T cell-recruiting antibodies which are potentially effective in hematologic malignancies have been derived from BiTEs. The elucidation of mechanisms of BiTE action and neonatal techniques used for the construction of BsAbs can improve the treatment of hematological malignancies. This review summarized the features of bispecific T cell-recruiting antibodies for the treatment of hematologic malignancies with special focus on preclinical experiments and clinical studies.
DOI: 10.1182/blood.2019004701
发表时间: 2020-11-19
期刊: BLOOD
影响因子: 20.3
作者:
Bartlett, Nancy L.;Herrera, Alex F.;Ansell, Stephen M.
通讯作者: Ansell, Stephen M.
DOI: 10.1158/1078-0432.ccr-17-2265
发表时间: 2018-06-01
影响因子: 11.5
作者:
Campagne, Olivia;Delmas, Audrey;Mager, Donald E.
通讯作者: Mager, Donald E.
DOI: 10.1126/science.1158545
发表时间: 2008-08-15
期刊: SCIENCE
影响因子: 56.9
作者:
Bargou, Ralf;Leo, Eugen;Kufer, Peter
通讯作者: Kufer, Peter
DOI: 10.1001/jamaoncol.2017.0580
发表时间: 2017-07-01
期刊: JAMA ONCOLOGY
影响因子: 28.4
作者:
Berry, Donald A.;Zhou, Shouhao;Radich, Jerald P.
通讯作者: Radich, Jerald P.
DOI: 10.1158/1078-0432.ccr-18-2752
发表时间: 2019-07-01
影响因子: 11.5
作者:
de Zafra, Christina L. Zuch;Fajardo, Flordeliza;Nolan-Stevaux, Olivier
通讯作者: Nolan-Stevaux, Olivier